Literature

Literature

Scientific Conferences:

View our past and upcoming scientific conferences here.

Galectin – Reviews:

Zetterberg F. (2023). Discovery of selective and orally available galectin-1 inhibitors. Journal of Medicinal Chemistry, 66(24), 16980-16990.
Leffler H. (2022). The life of a galectin: some questions about time, concentrations and affinities for its cellular and in vivo roles. Glycoforum. 25 (5), A12.
Bertuzzi, S., et al. (2020). Targeting Galectins With Glycomimetics. Frontiers in chemistry, 8, 593.
Johannes, L., Jacob, R., & Leffler, H. (2018). Galectins at a glance. Journal of cell science, 131(9).
Sciacchitano, S. et al. (2018). Galectin-3: One Molecule for an Alphabet of Diseases, from A to Z. International journal of molecular science, 19(2), 379
Nabi, I.R., Shankar, J., & Dennis, J.W. (2015). The galectin lattice at a glance. Journal of cell science,128(13), 2213-2219.
Li, L.C., Li, J., & Gao, J. Functions of galectin-3 and its role in fibrotic diseases. (2014). Journal of pharmacology and experimental therapeutics, 351(2), 336-343.
Mackinnon, A., et al. (2014). Design, synthesis, and applications of galectin modulators in human health: In C. Rademacher and P. H. Seeberger, (Eds.).Topics in Medicinal Chemistry: Carbohydrates as Drugs. Springer-Verlag GmbH & Co. KG, Berlin/Heidelberg, 95-121.
Leffler, H. & Nilsson, U. (2012). Low-Molecular Weight Inhibitors of Galectins. In A. A. Lyosov and P. G. Traber (Eds.). Galectins and Disease – Implications for Targeted Therapies. ACS Symp. Ser. No. 1115, 47-59.
Leffler, H., Carlsson, S., Hedlund, M., Qian, Y., & Poirier, F. (2004). Introduction to galectins. Glycoconjugate journal, 19(7-9), 433-40.

Galectin-3 & Fibrosis:

Galectins’ Role in Cancer

Galectin-3 & Other Diseases:

Galectin Modulators:

LOXL2 – Reviews:

Galecto, Inc. develops small molecules for the treatment of cancer and severe liver diseases. The company is built on nearly 15 years of research centering on the role of galectin-3 and the use of modulators of these proteins to treat cancer and severe liver diseases. These assets, combined with BRM-1420, a novel dual ENL-YEATS / FLT3 inhibitor, provide Galecto with a unique therapeutic platform.

Board

Management

Founders